Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 396

1.

Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.

Motheral B, Fairman KA.

Med Care. 2001 Dec;39(12):1293-304.

PMID:
11717571
2.
3.

The effect of incentive-based formularies on prescription-drug utilization and spending.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG.

N Engl J Med. 2003 Dec 4;349(23):2224-32.

4.

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG.

Arch Gen Psychiatry. 2005 Apr;62(4):435-41.

5.

The effect of a three-tier formulary on antidepressant utilization and expenditures.

Hodgkin D, Parks Thomas C, Simoni-Wastila L, Ritter GA, Lee S.

J Ment Health Policy Econ. 2008 Jun;11(2):67-77.

PMID:
18509214
6.
7.

Evaluation of the effect of a consumer-driven health plan on medical care expenditures and utilization.

Parente ST, Feldman R, Christianson JB.

Health Serv Res. 2004 Aug;39(4 Pt 2):1189-210.

8.
9.

Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.

Klepser DG, Huether JR, Handke LJ, Williams CE.

J Manag Care Pharm. 2007 Nov-Dec;13(9):765-77.

10.

Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.

Hartung DM, Carlson MJ, Kraemer DF, Haxby DG, Ketchum KL, Greenlick MR.

Med Care. 2008 Jun;46(6):565-72. doi: 10.1097/MLR.0b013e3181734a77.

PMID:
18520310
11.

A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.

Clark BE, Siracuse MV, Garis RI.

Res Social Adm Pharm. 2009 Jun;5(2):133-42. doi: 10.1016/j.sapharm.2008.06.002. Epub 2009 Jan 31.

PMID:
19524861
12.

The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees.

Huskamp HA, Deverka PA, Landrum MB, Epstein RS, McGuigan KA.

Health Serv Res. 2007 Oct;42(5):1926-42.

13.

Employer drug benefit plans and spending on prescription drugs.

Joyce GF, Escarce JJ, Solomon MD, Goldman DP.

JAMA. 2002 Oct 9;288(14):1733-9. Erratum in: JAMA 2002 Nov 20;288(19):2409.

PMID:
12365957
14.
15.

Approaches to pharmacy benefit management and the impact of consumer cost sharing.

Olson BM.

Clin Ther. 2003 Jan;25(1):250-72. Review.

PMID:
12637125
16.

The effect of a closed formulary on prescription drug use and costs.

Motheral BR, Henderson R.

Inquiry. 1999-00 Winter;36(4):481-91.

PMID:
10711322
17.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
18.

Trends in prescription drug expenditures by Medicaid enrollees.

Banthin JS, Miller GE.

Med Care. 2006 May;44(5 Suppl):I27-35.

PMID:
16625061
19.

Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease.

Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ.

J Manag Care Pharm. 2003 Mar-Apr;9(2):123-33.

20.

The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.

Hansen RA, Schommer JC, Cline RR, Hadsall RS, Schondelmeyer SW, Nyman JA.

Res Social Adm Pharm. 2005 Jun;1(2):139-57.

PMID:
17138472
Items per page

Supplemental Content

Write to the Help Desk